Cancer Genetics (CGIX) operates in a completely different space than Facebook (FB), and while other companies are postponing their IPOs or withdrawing them all together, this name is still looking to start trading this week. It’s possible that underwriters think because the offering is so small, there will still be plenty of available capital to participate in the IPO. Cancer Genetics is pricing 4 million shares in a range of $11.00 to $13.00. It hopes to raise $48 million, giving the company a total market cap of $111.9 million. The deal is underwritten by William Blair & Company, Baird, Needham & Company, and First Analysis Securities.
